NASDAQ · GH
Healthcare · Medical - Diagnostics & Research
$178.80
Down-$6.51 (-3.51%)
Updated Oct 31, 2026, 7:34 PM
SID Score
6.8/10
Composite research score
Smart Money
59/100
Neutral
Price performance · GH
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
GH closed at $178.80 after 21 trading sessions, up 0.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $182.48 | $185.645 | $175.4436 | $178.80 | 1.5M |
| Oct 29, 2026 | $185.17 | $186.0112 | $178.14 | $185.31 | 1.25M |
| Oct 28, 2026 | $178.06 | $186.03 | $177.00 | $182.59 | 2.32M |
| Oct 27, 2026 | $173.74 | $178.69 | $172.60 | $178.06 | 1.49M |
| Oct 26, 2026 | $170.10 | $175.08 | $168.73 | $173.25 | 2M |
| Oct 23, 2026 | $163.16 | $171.73 | $160.72 | $169.08 | 1.67M |
| Oct 22, 2026 | $165.03 | $167.25 | $158.6775 | $162.94 | 1.77M |
| Oct 21, 2026 | $162.29 | $171.22 | $162.00 | $166.66 | 2.54M |
| Oct 20, 2026 | $158.29 | $163.565 | $155.0688 | $162.59 | 1.31M |
| Oct 19, 2026 | $160.65 | $163.91 | $155.00 | $157.88 | 1.87M |
| Oct 16, 2026 | $165.88 | $168.47 | $157.435 | $158.60 | 1.98M |
| Oct 15, 2026 | $160.78 | $168.86 | $158.998 | $165.88 | 1.33M |
| Oct 14, 2026 | $159.89 | $166.16 | $159.00 | $162.99 | 1.28M |
| Oct 13, 2026 | $161.945 | $164.53 | $158.36 | $162.085 | 1.3M |
| Oct 12, 2026 | $168.26 | $168.69 | $158.46 | $162.79 | 1.56M |
| Oct 9, 2026 | $166.03 | $170.8099 | $166.03 | $167.47 | 1.52M |
| Oct 8, 2026 | $166.24 | $167.275 | $161.61 | $165.56 | 1.6M |
| Oct 7, 2026 | $166.50 | $171.55 | $165.00 | $168.33 | 2.2M |
| Oct 6, 2026 | $188.00 | $191.05 | $170.05 | $170.69 | 3.39M |
| Oct 5, 2026 | $177.45 | $187.69 | $176.37 | $187.22 | 1.75M |
| Oct 2, 2026 | $173.32 | $179.17 | $172.00 | $177.80 | 1.65M |
The latest Smart Investors Daily articles mentioning GH.
Company
Market Activity
Research & News
GH research
Company profile and research snapshot.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | BTIG | Buy | — |
| Oct 23, 2026 | Roth Capital | Buy | — |
| Oct 13, 2026 | Morgan Stanley | Overweight | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Oct 1, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 23, 2026
Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.
Yahoo · Oct 20, 2026
A Cancer Test Approval Meets a High Valuation Guardant Health, Inc. (NASDAQ:GH) is moving beyond identifying mutations at diagnosis toward testing patients repeatedly as their cancer changes. Recent FDA approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant in advanced breast cancer reinforces that shift. The financial opportunity is not merely another test […]
Yahoo · Oct 20, 2026
PALO ALTO, Calif., October 20, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Mad
SeekingAlpha · Oct 19, 2026
Guardant Healthâs oncology portfolio and Shield continue to help with its ongoing growth. It remains exposed to patent litigation risks. I rate GH stock as Hold. Read my update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GH.
